vs
EXACT SCIENCES CORP（EXAS）与CHART INDUSTRIES INC（GTLS）财务数据对比。点击上方公司名可切换其他公司
CHART INDUSTRIES INC的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.1B vs $878.4M），CHART INDUSTRIES INC净利率更高（5.0% vs -9.8%，领先14.8%），EXACT SCIENCES CORP同比增速更快（23.1% vs -2.5%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $66.2M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Oricon Inc.成立于1999年，是日本知名音乐产业集团的控股主体，主营日本本土及西洋音乐相关的行业资讯与数据统计服务。其前身为小池宗光于1967年11月创立的Original Confidence公司，凭借权威音乐排行榜广为人知，2002年4月正式承接原公司旗下的Oricon唱片排行榜业务。
EXAS vs GTLS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $53.6M |
| 毛利率 | 70.1% | 33.3% |
| 营业利润率 | -9.4% | 11.6% |
| 净利率 | -9.8% | 5.0% |
| 营收同比 | 23.1% | -2.5% |
| 净利润同比 | 90.1% | -32.7% |
| 每股收益（稀释后） | $-0.45 | $1.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | $1.1B | ||
| Q2 25 | $811.1M | $1.1B | ||
| Q1 25 | $706.8M | $1.0B | ||
| Q4 24 | $713.4M | $1.1B | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $1.0B | ||
| Q1 24 | $637.5M | $950.7M |
| Q4 25 | $-86.0M | $53.6M | ||
| Q3 25 | $-19.6M | $-138.5M | ||
| Q2 25 | $-1.2M | $76.1M | ||
| Q1 25 | $-101.2M | $49.5M | ||
| Q4 24 | $-864.6M | $79.6M | ||
| Q3 24 | $-38.2M | $69.0M | ||
| Q2 24 | $-15.8M | $58.6M | ||
| Q1 24 | $-110.2M | $11.3M |
| Q4 25 | 70.1% | 33.3% | ||
| Q3 25 | 68.6% | 34.1% | ||
| Q2 25 | 69.3% | 33.6% | ||
| Q1 25 | 70.8% | 33.9% | ||
| Q4 24 | 69.0% | 33.6% | ||
| Q3 24 | 69.4% | 34.1% | ||
| Q2 24 | 69.8% | 33.8% | ||
| Q1 24 | 70.0% | 31.8% |
| Q4 25 | -9.4% | 11.6% | ||
| Q3 25 | -3.0% | -8.0% | ||
| Q2 25 | -0.3% | 15.7% | ||
| Q1 25 | -13.6% | 15.2% | ||
| Q4 24 | -122.8% | 17.0% | ||
| Q3 24 | -5.6% | 16.8% | ||
| Q2 24 | -3.8% | 16.1% | ||
| Q1 24 | -16.7% | 11.9% |
| Q4 25 | -9.8% | 5.0% | ||
| Q3 25 | -2.3% | -12.6% | ||
| Q2 25 | -0.1% | 7.0% | ||
| Q1 25 | -14.3% | 4.9% | ||
| Q4 24 | -121.2% | 7.2% | ||
| Q3 24 | -5.4% | 6.5% | ||
| Q2 24 | -2.3% | 5.6% | ||
| Q1 24 | -17.3% | 1.2% |
| Q4 25 | $-0.45 | $1.06 | ||
| Q3 25 | $-0.10 | $-3.23 | ||
| Q2 25 | $-0.01 | $1.53 | ||
| Q1 25 | $-0.54 | $0.94 | ||
| Q4 24 | $-4.69 | $1.57 | ||
| Q3 24 | $-0.21 | $1.33 | ||
| Q2 24 | $-0.09 | $1.10 | ||
| Q1 24 | $-0.60 | $0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $366.0M |
| 总债务越低越好 | — | $3.7B |
| 股东权益账面价值 | $2.4B | $3.2B |
| 总资产 | $5.9B | $9.8B |
| 负债/权益比越低杠杆越低 | — | 1.13× |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $366.0M | ||
| Q3 25 | $1.0B | $399.2M | ||
| Q2 25 | $858.4M | $342.3M | ||
| Q1 25 | $786.2M | $296.2M | ||
| Q4 24 | $1.0B | $308.6M | ||
| Q3 24 | $1.0B | $310.2M | ||
| Q2 24 | $946.8M | $247.4M | ||
| Q1 24 | $652.1M | $191.9M |
| Q4 25 | — | $3.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.4B | $3.2B | ||
| Q3 25 | $2.5B | $3.2B | ||
| Q2 25 | $2.5B | $3.4B | ||
| Q1 25 | $2.4B | $3.0B | ||
| Q4 24 | $2.4B | $2.8B | ||
| Q3 24 | $3.2B | $3.0B | ||
| Q2 24 | $3.2B | $2.7B | ||
| Q1 24 | $3.1B | $2.7B |
| Q4 25 | $5.9B | $9.8B | ||
| Q3 25 | $5.9B | $9.8B | ||
| Q2 25 | $5.8B | $9.7B | ||
| Q1 25 | $5.7B | $9.3B | ||
| Q4 24 | $5.9B | $9.1B | ||
| Q3 24 | $6.7B | $9.5B | ||
| Q2 24 | $6.7B | $9.3B | ||
| Q1 24 | $6.4B | $9.2B |
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $88.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $66.2M |
| 自由现金流率自由现金流/营收 | 13.7% | 6.1% |
| 资本支出强度资本支出/营收 | 3.6% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.66× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $202.8M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $88.8M | ||
| Q3 25 | $219.9M | $118.0M | ||
| Q2 25 | $89.0M | $145.9M | ||
| Q1 25 | $30.8M | $-60.0M | ||
| Q4 24 | $47.1M | $281.4M | ||
| Q3 24 | $138.7M | $200.6M | ||
| Q2 24 | $107.1M | $116.1M | ||
| Q1 24 | $-82.3M | $-95.1M |
| Q4 25 | $120.4M | $66.2M | ||
| Q3 25 | $190.0M | $94.7M | ||
| Q2 25 | $46.7M | $122.0M | ||
| Q1 25 | $-365.0K | $-80.1M | ||
| Q4 24 | $10.7M | $260.9M | ||
| Q3 24 | $112.6M | $174.5M | ||
| Q2 24 | $71.2M | $88.0M | ||
| Q1 24 | $-120.0M | $-141.2M |
| Q4 25 | 13.7% | 6.1% | ||
| Q3 25 | 22.3% | 8.6% | ||
| Q2 25 | 5.8% | 11.3% | ||
| Q1 25 | -0.1% | -8.0% | ||
| Q4 24 | 1.5% | 23.6% | ||
| Q3 24 | 15.9% | 16.4% | ||
| Q2 24 | 10.2% | 8.5% | ||
| Q1 24 | -18.8% | -14.9% |
| Q4 25 | 3.6% | 2.1% | ||
| Q3 25 | 3.5% | 2.1% | ||
| Q2 25 | 5.2% | 2.2% | ||
| Q1 25 | 4.4% | 2.0% | ||
| Q4 24 | 5.1% | 1.9% | ||
| Q3 24 | 3.7% | 2.5% | ||
| Q2 24 | 5.1% | 2.7% | ||
| Q1 24 | 5.9% | 4.8% |
| Q4 25 | — | 1.66× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | -1.21× | ||
| Q4 24 | — | 3.54× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | -8.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GTLS
| Repair Service And Leasing Segment | $330.4M | 31% |
| Heat Transfer Systems Segment | $325.8M | 30% |
| Specialty Products Segment | $259.5M | 24% |
| Transferred Over Time | $94.4M | 9% |
| Transferred At Point In Time | $69.5M | 6% |
